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Simple Summary: Oncogenic KrasG12D and tumor inflammation are critical components of the
development and dissemination of pancreatic ductal adenocarcinoma (PDAC). The aim of this study
is to investigate a lesser-known cytokine, CCL15, that functions as a new downstream target of
KrasG12D with the purpose of regulating PDAC cell migration and invasion. We showed increased
levels of CCL15 as well as the presence of its receptors, including CCR1 and CCR3, in PDAC tissues
and cell lines. The knockdown of CCL15 diminished metastatic Panc-1 cell migration, whereas the
treatment of CCL15 in non-metastatic BxPC-3 cells promoted BxPC-3 cell motility. Similar results
were verified using murine metastatic PDAC KP-2 cells. Furthermore, we demonstrated that
CCL15-modulated PDAC cell migration through the upregulation of cellular reactive oxygen species
(ROS) levels and the knockdown of KrasG12D resulted in a decrease in CCL15. Altogether, our data
unveiled a new mechanism of oncogenic KrasG12D in modulating PDAC inflammation and spreading.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is well known for its high death rate due to
prompt cancer metastasis caused by cancer cell migration and invasion within the early stages of
its development. Here, we reveal a new function of cytokine CCL15, namely the upregulation of
PDAC cell migration and invasion. We showed increased levels of CCL15 transcripts and protein
expressions in human PDAC tissue samples, as well as in cultured cell lines. Furthermore, PDAC
cells also expressed CCL15 receptors, including CCR1 and CCR3. Murine PDAC cell lines and tissues
strengthened this finding. The manipulation of CCL15 in metastatic Panc-1 cells through CCL15
knockdown or CCL15 neutralization decreased Panc-1 cell motility and invasiveness. In addition,
treating non-metastatic BxPC-3 cells with recombinant CCL15 accelerated the cell migration of BxPC-3.
A reduction in the levels of reactive oxygen species (ROS) by either N-Acetyl-L-Cysteine treatment or
p22phox knockdown led to a decrease in Panc-1 cell migration and a reversed effect on recombinant
CCL15-promoted BxPC-3 cell movement. Importantly, the knockdown of oncogenic Kras in Panc-1
cells abolished CCL15 protein expression and impeded cell migration without affecting PDAC cell
growth. Altogether, our work elucidates an additional molecular pathway of oncogenic Kras to
promote PDAC metastasis through the upregulation of cell migration and invasion by the Kras
downstream CCL15, a lesser-known cytokine within the cancer research field.
Keywords: CCL15; KrasG12D ; pancreatic ductal adenocarcinoma; cell migration; cell invasion;
metastasis; reactive oxygen species
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer,
with a dismal five-year survival rate of around 7%. Late diagnosis in clinical settings
is common, as is the early metastasis of cancer cells to other parts of the body, limiting
therapeutic options and contributing to the high death rate. PDAC is a disorder of oncogenic
Kras, a characteristic that is substantiated by the 90% of patients with PDAC harboring
oncogenic Kras mutations. Furthermore, turning off Kras mutants in transgenic PDAC
mice reversed cancer cells back to normal pancreatic acinar cells [1–3]. Initially, cancer
metastasis involves an increase in cancer cell migration and invasion that allows local
cancer cells to physically leave the original site. To maintain their increased migration and
mobile abilities, cancer cells undergo epithelial-mesenchymal transition (EMT) to alter the
cell–cell adhesion and the apical–basal polarity [4–7]. Key molecules positively associated
with EMT, such as YAP, TAZ, and Snail, have been detected in PDAC [8–10].
Cytokine CCL15 has been reported to play a role in asthma through IgE-regulated
immunomodulation since high levels of CCL15 detected in the serum samples of patients
with severe asthma can be diminished by a humanized anti-IgE antibody [11,12]. However,
so far, very little is known about this cytokine as it pertains to the cancer research field.
The most well-known function of CCL15 is its chemotactic ability to attract neutrophils,
monocytes, and lymphocytes to re-shape the tumor microenvironment [10,13]. Although a
few reports showed that overexpressed CCL15 in cancer cells may be used as an indicator of
poor patient outcomes of hepatocellular carcinoma and colorectal cancer metastasis [14–17],
the mechanisms used by CCL15 within cancer cells to regulate their metastatic abilities
remain unclear.
We, herein, showed that increased expressions of CCL15 were detected in human and
murine metastatic PDAC cells. Results from the TCGA Genomic database suggested that
patients with PDAC with the CCL15 copy number amplification had poor clinical outcomes
as compared to those without the amplification. Both CCR1 and CCR3, which are receptors
for CCL15, were present in PDAC cells. A blockade of CCL15 in human metastatic PDAC
Panc-1 cells, either through CCL15 knockdown or CCL15 neutralization, significantly
impeded cancer cell motility as well as invasion. Similarly, the knockdown of CCL9, an
orthologue of human CCL15 in murine metastatic PDAC KP-2 cells, attenuated their cell
migratory ability. On the other hand, the addition of exogenous recombinant CCL15 to
non-metastatic BxPC-3 cells accelerated the cell migration of BxPC-3. Interestingly, treating
human PDAC cells with a general ROS scavenger, NAC, reduced the CCL15-mediated cell
migration of PDAC. Furthermore, the knockdown of Kras in human Panc-1 cells suppressed
CCL15 protein expression, suggesting that CCL15 functions downstream of oncogenic
KRasG12D in PDAC. In summary, our data not only unveil a new function of CCL15,
which is to regulate PDAC cell migration and invasion, but also elucidates another new
mechanistic regulation that oncogenic Kras mutants use to promote PDAC cell metastasis
through CCL15 and its subsequent ROS production.
2. Materials and Methods
2.1. Cell Lines, Antibodies, and Reagents
Human pancreatic ductal adenocarcinoma (PDAC) cell lines, including BxPC-3, Panc-1,
and CFPAC-1, were obtained from ATCC (Manassas, VA, USA) and cultured according
to the instructions of ATCC. Murine pancreatic ductal cells GA36 were derived from
six-week-old Pdx1cre/+ /KrasG12D/+ mice as previously described [18], cultured on collagen
I-coated dishes, and maintained in DMEM/F-12 media with 15 mM HEPES with supplements of 5 mg/mL D-glucose, 1.22 mg/mL nicotinamide, 5 nM 3,3,5-tri-iodo-L-thyronine,
1 µM dexamethasone, 100 ng/mL cholera toxin, 5 mL/L insulin-transferrin-selenium,
0.1 mg/mL soybean trypsin inhibitor type I, 20 ng/mL EGF, 5% NuSerum IV, and 25 µg/mL
bovine pituitary extract. Murine PDAC cells KP2 were cultured on collagen I-coated plates
and maintained as previously described [19,20]. All cells were maintained in a 37 ◦ C incubator with 5% CO2 . CCL15 antibody was purchased from Abcam (Cambridge, UK). Both
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CCR1 and CCR3 antibodies were from Novus Biologicals (Littleton, CO, USA). N-cadherin
antibody was purchased from Thermo Fisher Scientific (Waltham, MA, USA) and antibodies of vimentin and p22phox were from Cell Signal Technology (Danvers, MA, USA).
Antibodies of actin and GAPDH were from Santa Cruz Biotechnology (Dallas, TX, USA).
Kras antibody was purchased from ProteinTech (Rosemont, IL, USA). Recombinant CCL15and CCL15-neutralizing antibodies were from PeproTech (Cranbury, NJ, USA) and R&D
Systems (Minneapolis, MN, USA), respectively. N-Acetyl Cysteine was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Other reagents used are described in the specific
experiment sections.
2.2. Gene Knockdown
Lentiviral plasmids encoding shKras, shCCL15, shCCL9, and scramble were purchased
from Sigma-Aldrich (St. Louis, MO, USA) with the following TRC clone ID numbers.
For shKras, TRCN0000040149 (labeled as shKras#1) and TRCN 0000040151 (labeled as
shKras#2); for shCCL15, TRCN0000377734 (labeled as shCCL15#1) and TRCN0000371599
(labeled as shCCL15#2); for shCCL9, TRCN0000077010 (labeled as shCCL9#1) and
TRCN0000077012 (labeled as shCCL9#2). Lentivirus was produced in 293FT cells that
were transfected with the plasmid as described above and ViraPower Packaging Mix
(Invitrogen; Waltham, MA, USA) using Lipofectamine 2000, and lentiviral titers were determined according to the manufacturer’s instructions. Cells were infected with shKras,
shCCL15, shCCL9, or shScramble lentiviruses in the presence of 6 µg/mL fresh polybrene
for 24 h. After 24 h, the media containing lentiviruses were removed and replenished with
fresh complete media. 72 h post-infection, fresh complete media containing appropriate
antibiotics were added to select knockdown cells and changed every 2–3 days. One week
after antibiotic selection, cells in pool were collected for real-time quantitative RT-PCR or
immunoblotting to assess gene knockdown efficiency.
2.3. Cell Lysates Collection and Immunoblotting
Cells were rinsed twice with cold PBS, lysed in buffer A (50 mM Tris/HCl [pH 7.4],
1% TritonX-100, 150 mM NaCl, and 5 mM EDTA [pH 7.4]) or RIPA buffer (25 mM Tris/HCl
[pH 7.5], 1% Triton X-100, 140 mM NaCl, 1 mM EDTA, 0.5% SDS) supplemented with a
protease inhibitor cocktail (Thermo Fisher Scientific), vortexed with the maximal speed for
1 min, incubated on ice for 10 min, and centrifuged at 4 ◦ C, 14,000 rpm for 10 min. The
supernatants were denatured, followed by SDS-PAGE. Resolved proteins were transferred
onto nitrocellulose membranes followed by blocking in 5% BSA in TBST (50 mM Tris.HCl
[pH 7.6], 150 mM NaCl, 0.05% Tween 20) and incubated with the antibodies of interest in
5% BSA in TBST overnight at 4 ◦ C. The appropriate horseradish peroxidase-conjugated
secondary antibodies were added to the membranes for 30 min at room temperature.
Images were captured and visualized with ECL and X-ray film.
2.4. RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from cells using the RNeasy kit from Qiagen (Hilden, Germany)
according to the manufacturer’s instructions. Levels of mRNA of interest were examined
using a 2-step quantitative reverse transcriptase-mediated real-time PCR (qPCR) method.
An equal amount of total RNA was converted to cDNA by the high-capacity cDNA reverse
transcriptase kit (Applied Biosystems, Bedford, MA, USA). Real-time quantitative PCR
was performed in a CFX Connect real-time PCR detection system (Bio-Rad) using the
TaqMan Universal PCR master mix (Applied Biosystems) with probe/primer sets and the
following PCR program: 95 ◦ C for 20 s, 40 cycles of 95 ◦ C for one second, and 60 ◦ C for
20 s. All Taqman probe/primer sets were purchased from Applied Biosystems (CCL15:
Mm01302419_m1; CCL9: Mm00441260_m1; GAPDH: Mm99999915_g1 for mouse and
Hs99999905_m1 for human). The collected data were analyzed by Sequence Detection System software (Bio-Rad) and normalized to GAPDH. The mRNA abundance was calculated
using the ∆∆CT method.
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2.5. Immunohistochemistry
Human pancreatic tissue slides, including normal and cancer tissue samples, were
obtained from BioChain (Newark, CA, USA) and US Biomax (Derwood, MD, USA). All
experiments that involved using human tissue samples were carried out according to
the IRB protocol approved by the CAU IRB committee. Slides were deparaffinized in
xylene and gradually re-hydrated through 100% alcohol to distilled water. The re-hydrated
slides were subjected to heat-induced antigen retrieval in the antigen retrieval buffer,
10 mM sodium citrate buffer (pH 6.0) or 10 mM Tris. Slides were then incubated with
3% hydrogen peroxide followed by PBS wash. Slides were treated with protein block serumfree solution (DAKO) for 10 min at room temperature. After the primary antibody (CCL15
1:400 (Abcam); CCR1 1:100 (Novus Biologicals); CCR3 1: 200 (Abcam)) was incubated with
slides, the ImmPRESS Polymer Detection Kit (Vector Laboratories; Burlingame, CA, USA)
was used according to the manufacturer’s instructions. Images were collected using the
Aperio VERSA tissue scanner with ImageScope software (Aperio; Sausalito, CA, USA). For
specificity of CCR1 and CCR3 antibody, see Figure S10.
2.6. Measurement of Cellular ROS Levels
1 × 104 cells/well of BxPC-3 or Panc-1 cells were seeded in a 96 black well plate with a
clear bottom. The following day, the cells were labeled with 20 µM H2 DFFDA in complete
media at 37 ◦ C for 20 min. Cells were then washed 3 times with pre-warmed Live Cell
Imaging Solution (Thermo Fisher Scientific). After the final wash, cellular ROS levels were
measured in Live Cell Imaging Solution using the Synergy H1 Hybrid Microplate Reader
(Agilent Technologies; Santa Clara, CA, USA) at 485/528 (Ex/Em) nm. For treatments of
recombinant CCL15 (100 ng/mL) or CCL15 neutralizing antibody (NAb) (5 µg/mL), cells
were treated for 24 h before H2 DFFDA labeling and subsequent cellular ROS measurement
as described above.
2.7. Wound Healing Assay/Cell Migration Assay
6 × 104 BxPC-3 or Panc-1 cells were seeded in each well of the 2-well culture-insert
placed in a 24-well plate and allowed to reach confluence prior to the removal of the
culture-inserts. The cells were then washed with PBS twice, and appropriate growth media
containing 1% FBS was carefully added to the well to allow cells to migrate into the gap
caused by the culture-insert (set as 0 h). For testing the recombinant CCL15 effect on
BxPC-3 migration, 1 × 105 BxPC-3 cells were used in the described wound healing assay.
For KP2 cell migration, 1 × 105 cells were seeded in each well of the 2-well culture-insert
into a collagen I-coated 24-well plate used in the procedure described above. Images were
captured using a Zeiss Axiovert 200M inverted microscope with a 10× objective lens at the
indicated time points. The area of the culture-insert gap was recorded. At each indicated
time point, the area of the gap was measured using image J software, while the migrated
area was calculated based on the difference between the area recorded at t = 0 and the
empty area at the indicated time point. The final number was recorded as a percentage of
migrated area compared to t = 0, the initial area prior to migration.
2.8. Cell Growth Assay
1 × 105 cells were seeded in a 12-well plate in complete media containing puromycin
to maintain the knockdown of the indicated gene. Cells were trypsinized, and alive cell
numbers were counted using the trypan blue exclusion method every 24 h up to 96 h. Each
time point indicated was quantified by three separate wells.
2.9. Cell Invasion Assay
The indicated Panc-1 cells were serum starved in the serum-free media for 24 h,
detached from cell culture dishes by trypsin/EDTA, counted, and re-suspended in serumfree media containing 0.1% BSA at a density of 1 × 106 cells/mL. A quantity of 750 µL
serum-free media containing 0.1% BSA and 1 ng/mL EGF was added to each bottom well
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of the Corning BioCoat Matrigel Invasion Chamber. The matrigel-coated insert (8 µm
pore size) was placed on top of each well in the 24-well Corning BioCoat Chamber plate
and 200 µL of cell solution was added to each insert. The whole plate was returned to
the cell culture incubator for 16 h. At the end point, the inserts were vigorously washed
with PBS twice, and cells on each side of the membrane of the insert were fixed with
3.7% formaldehyde in PBS at room temperature for 2 min. Membranes of the inserts were
then washed with PBS twice. Cells on the membrane were permeabilized in 100% methanol
at room temperature for 20 min, washed with PBS twice, and stained with Giemsa at room
temperature for 15 min in the dark. After another wash with PBS, un-invasive cells that
were on the top side of the membrane were removed by cotton swabs. Images of the
invaded cells on the bottom of the membrane of the insert were collected using a Zeiss
Axiovert 200M inverted microscope with a 20× objective lens. The number of invasive cells
was counted in five randomly selected fields per condition.
2.10. Statistical Analysis
Data are presented as means ± SE. p-values were acquired with the Student’s t-test
for comparing 2 sets of data using Prism (GraphPad Software, San Diego, CA, USA). For
more than 2 sets of data, one-way ANOVA analysis along with multiple comparisons was
carried out using Prism (GradPad Software). p < 0.05 is considered statistically significant.
3. Results
3.1. Elevated Expression of CCL15 and Its Receptors in Human PDAC
Based on the results of our microarray experiments, CCL15 was identified as a topranked target involved in the cancer progression of PDAC. So far, there is very limited
information on CCL15 function within physiological and pathological settings; therefore,
we first utilized the TCGA database of Cancer Genomics to assess the role of CCL15 in pancreatic cancer (http://www.cancer.gov/tcga, accessed on 19 April 2022). Among all types
of pancreatic cancer, including pancreatic adenocarcinoma, pancreatic neuroendocrine
tumors, and undifferentiated pancreatic carcinoma found in the database, which were
extracted from 596 patient samples of three PDAC studies, it showed that CCL15 gene amplification was only detected in pancreatic adenocarcinoma (Figure S1A). Although CCL15
showed a low frequency rate of 2.5%, it did suggest specificity to PDAC. Moreover, with the
available data, we found that patients with PDAC with CCL15 amplification demonstrated
significantly shorter median survival than those without amplification (4.7 vs. 20.2 months,
p = 0.00184) (Figure S1B). Altogether, these data indicate the importance of CCL15 in
human PDAC.
To further verify the idea that CCL15 plays a role in PDAC, we evaluated CCL15
expression in human PDAC tissue samples through immunohistochemistry. As shown
in Figure 1A, the increased expression of CCL15 was present in human PDAC tissues
as compared to the normal human pancreas. It has been reported that CCR1 and CCR3
function as specific receptors for cytokine CCL15 resulting in biological functions through
the ligand-receptor interaction [13,21,22]. We also detected the expression of both CCR1
and CCR3 in PDAC cells of human tissue samples (Figure 1B,C).
3.2. Upregulation of CCL15 in Metastatic PDAC Cells versus Non-Metastatic PDAC Cells
One of the critical features of PDAC in clinical settings is its early metastasis to other organs, which is highly associated with cancer cell migration and invasion. To assess if CCL15
plays a role in cancer metastasis, we first examined the levels of CCL15 mRNA and protein
expression in cultured human PDAC cell lines that have different metastatic abilities when
implanted into mice [23–25]. These included non-metastatic BxPC-3 and metastatic Panc-1
and CFPAC-1 cells. We detected a higher expression of CCL15 transcripts as well as proteins in Panc-1 and CFPAC-1 cells, both of which are metastatic rather than non-metastatic
BxPC-3 cells (Figure 2A,B). In addition, all three human PDAC cell lines expressed the
CCL15 receptors CCR1 and CCR3 (Figure 2C). Similarly, the levels of CCL9, an orthologue
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of human CCL15, were elevated in murine metastatic PDAC KP-2 cells [19,20] as compared
6 of 17
to those in murine pancreatic ductal GA36 cells (Figure 2C). Furthermore, the increased expression of CCL9 was detected in metastatic PDAC cells of pdx1CRE+ /KrasG12D /p53R172H
(KPC) mice in comparison to adjacent normal acini of the pancreas (Figure S2). Altogether,
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3.2. Upregulation of CCL15 in Metastatic PDAC Cells Versus Non-Metastatic PDAC Cells
3.3. CCL15-Modulated PDAC Cell Migration through Reactive Oxygen Species (ROS)
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migration assay as described above (Figure S4). To further strengthen our results from Panc1 cells, we knocked down CCL9 in murine metastatic PDAC KP-2 cells using a lentiviral
shRNA delivery system. As shown in Figure 3D, KP-2 cells infected by lentiviruses carrying
shCCL9 #1 or shCCL9 #2 had decreased levels of CCL9 transcripts, down to 25–50% as
compared to the control. Furthermore, these KP-2 cells with decreased CCL9 transcripts
showed reduced cell migration abilities (Figure 3E). The blockade of CCL15 can be mediated
through CCL15 gene knockdown or the neutralization of CCL15 via a CCL15-neutralizing
antibody (NAb). We then tested Panc-1 cell migration abilities in the presence of a CCL15
NAb or a control isotype antibody. As shown in Figure 3F, neutralization of CCL15
7 of in
17
Panc-1 cells significantly impeded their migration ability. Furthermore, treating BxPC-3
cells with exogenously added recombinant CCL15 accelerated BxPC-3 mobility (Figure 3G).

Figure 2. Upregulation of CCL15 levels in metastatic PDAC cells. (A) Levels of CCL15 mRNA in
Figure 2. Upregulation of CCL15 levels in metastatic PDAC cells. (A) Levels of CCL15 mRNA in
human PDAC cell lines (BxPC-3: non-metastatic; Panc-1 and CFPAC-1: metastatic) were assessed
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3.3. CCL15-Modulated PDAC Cell Migration through Reactive Oxygen Species (ROS)
Next, we assessed the migration ability of metastatic Panc-1 cells and non-metastatic
BxPC-3 cells using the wound-healing assay. As expected, Panc-1 cells that contained increased levels of CCL15 migrated faster than BxPC-3 cells, filling in the vacant areas at a
quicker rate (Figure 3A). To validate the link between CCL15 and PDAC cell migration,
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abilities at the indicated time points. *: p < 0.05 as compared to shScramble at same migration
time point. (D) Levels of CCL9, an orthologue of human CCL15, in murine PDAC KP2 cells stably
expressing shScramble, shCCL9 #1, or shCCL9 #2 were examined by real-time qRT-PCR. *: p < 0.05
as compared to shScramble. (E) Murine PDAC KP2 cells stably expressing shScramble, shCCL9 #1,
or shCCL9 #2 were subjected to a cell migration assay. The cells were allowed to migrate for 19 h
after removal of culture-inserts. *: p < 0.05 as compared to shScramble. (F) Panc-1 cells were treated
either with a control isotype neutralizing antibody or a CCL15 NAb (5 µg/mL) followed by cell
migration assay. *: p < 0.05 as compared to control isotype NAb. (G) BxPC-3 cells treated with either
ddH2 O/control or 50 ng/mL recombinant CCL15 were subjected to a cell migration assay for 20 h.
*: p < 0.05 as compared to control. Original blots see Supplementary File S1.

As shown in Figure 4A, the levels of cellular ROS in Panc-1 cells were higher than
those in BxPC-3 cells, which is positively associated with CCL15 expression as well as
cell migration ability in these cells. Given that CCL15 is an inflammatory cytokine that
associates with reactive oxygen species (ROS), we next tested whether the cellular ROS
levels of Panc-1 and/or BxPC-3 cells are regulated by cytokine CCL15. When Panc-1 cells
were treated with a specific CCL15 NAb, it reduced cellular ROS levels by 50% as compared
to those treated with a control isotype NAb (Figure 4B). In contrast, the treatment of recombinant CCL15 significantly enhanced ROS production in BxPC-3 cells (Figure 4C). These
results suggested a correlation among CCL15, ROS, and PDAC cell migration; therefore,
we next examined whether ROS were involved in the cell motility of PDAC. When treating
Panc-1 cells with the general ROS scavenger N-acetyl-L-cysteine (NAC), the migration
speed of Panc-1 cells filling vacant areas was diminished (Figure 4D). The reduced cell
migration ability of Panc-1 under NAC treatment was not due to the decreased cell proliferation of Panc-1 (Figure S5). Cellular ROS can be generated from many organelles such
as mitochondria, endoplasmic reticulum, etc., and through cellular oxidative processes,
including the activity of NADPH oxidases (NOXs) [26,27]. To determine whether NOXs
were associated with PDAC cell motility, we knocked down p22phox, a critical component of NOXs [28,29] in Panc-1 cells, and examined the cell migration abilities of Panc-1
cells stably expressing shp22phox as well as Panc-1 shScramble control cells. As shown
in Figure 4E and Figure S6, the knockdown of p22phox diminished Panc-1 cell mobility.
To further dissect the relationship between ROS and CCL15-mediated cell migration, we
treated BxPC-3 cells with recombinant CCL15, NAC, or both. As expected, treating BxPC-3
cells with exogenously added recombinant CCL15 accelerated their cell migratory ability,
whereas NAC dramatically reduced it (Figure 4F). In addition, a dual treatment of NAC
and recombinant CCL15 in BxPC-3 cells had the same effect as that of NAC treatment
alone, suggesting that ROS are required for CCL15-mediated PDAC cell migration. Altogether, these data suggested that CCL15 promoted the cell mobility of PDAC through the
upregulation of ROS.
3.4. CCL15 Promoted PDAC Cell Migration and Invasion and Was Mediated through Oncogenic Kras
Our results imply that oncogenic Kras mutation has the ability to regulate PDAC
cellular migration by utilizing the CCL15/ROS axis. To further investigate this possibility,
we knocked down KrasG12D in highly migratory Panc-1 cells using lentiviral-delivered
shRNA sequences that specifically target Kras and then assessed CCL15 expression as well
as the cell migration ability in these cells (Figure 5A,B; Figure S7). As shown in Figure 5A,
when 50% of Kras was knocked down, a simultaneous decrease in CCL15 expression in
Panc-1cells was observed, suggesting that CCL15 is a downstream target of oncogenic
KrasG12D . In addition, the knockdown of KrasG12D significantly slowed the cell migration
of Panc-1 by approximately 70% as compared to the control Panc-1 cells (Figure 5B), while
similar observations were witnessed for CCL15 knockdown (Figure 3C). To assess whether
KrasG12D or CCL15 participates in PDAC cell growth, we also measured cell proliferation
in the cells of Panc-1 of shscramble, shKras, and shCCL15. Neither the knockdown of Kras
nor that of CCL15 affected Panc-1 cell growth (Figure 5C,D).
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Cancer metastasis requires cancer cells to invade the surrounding extracellular matrix
and migrate out of the primary cancer site as the initial steps to reaching other organs.
Prior to their invasion, cancer cells must detach from the epithelium while becoming more
mobile via the epithelial mesenchymal transition (EMT) process. To test whether CCL15
can also regulate PDAC cell invasion, we evaluated the invasion ability of Panc-1 cells
that stably expressed shCCL15 on matrigel. As shown in Figure 6A, decreased numbers of
Panc-1 cells that had reduced levels of CCL15 expression (Figure 3B) invaded through a
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matrigel-coated membrane in comparison to the control cells, Panc-1 shScramble. Similarly,
the neutralization of CCL15 from Panc-1 cells using a CCL15 NAb significantly suppressed
their invasion into the matrigel (Figure 6B). To test the possibility of EMT regulation via
CCL15, we utilized well-known EMT markers, including N-cadherin and vimentin, both
of which are expressed by mensenchymal cells with high migratory abilities. As shown
in Figure 6C and Figure S8, the knockdown of CCL15 reduced the expression levels of
N-cadherin and vimentin. The same result was also observed in murine PDAC KP-2
cells when CCL9, a murine orthologue of CCL15, was knocked down (Figure S9), thus
suggesting that this cytokine plays a critical role in the EMT process. Altogether, these
data suggested that CCL15 positively regulates EMT to promote the cell invading ability
of PDAC.
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4. Discussion
Inflammation that causes elevated levels of ROS is pivotal to cancer initiation, development, and metastasis. In general, it is believed that ROS contribute to tumor progression
through increased genomic instability [30]. It has been shown that oncogenes such as
HRasV12, Kras, and c-Myc increase ROS levels in cancer cells [31]. During pancreatic cancer initiation, oncogenic KrasG12D transdifferentiates acinar cells to a proliferating duct-like
progenitor phenotype that later develops into pancreatic precancerous lesions through
mitochondrial ROS [32]. Besides oncogenes, tumor suppressor genes such as p53, p21, and
p16 also regulate ROS in non-cancerous cells by rendering them adapted to remodeled
redox balance, which includes the upregulation of anti-oxidative as well as pro-apoptotic
genes [33–37]. In addition, it has also been reported that tumor suppressor genes commonly
lost in cancer metastasis modulate cell mobility and invasion. For example, the introduction
of BTG2, a tumor suppressor gene lost in metastatic lung and prostate cancers, repressed
cell migration and cancer invasion by the inhibition of mitochondrial ROS as well as Src
activity [38].
Redox regulation, especially through ROS production, is well known to modulate
cellular migration and adhesion process [39]. Our data showed that a general ROS scavenger, N-Acetyl-L-Cysteine (NAC), dramatically reduced the cell migration of Panc-1 cells
that expressed high levels of CCL15 (Figure 4D). Furthermore, the decrease in the cell
migratory abilities of Panc-1 in the presence of a depleting ROS was not due to reduced cell
proliferation of Panc-1 (Figure S5). In fact, we actually detected a higher DNA content of
Panc-1 treated with NAC in comparison to the control cells; this result further supports
the conclusion that ROS positively modulates Panc-1 cell migration. Interestingly, the
depletion of ROS through the knockdown of p22phox, a key component of NOXs controlling cellular ROS levels [28,40], also slowed down Panc-1 cell migration (Figure 4E),
suggesting that NOXs are one of the resources used by ROS to mediate PDAC cell migration. Not surprisingly, it has been demonstrated that the knockdown of Nox4 blocked
TGF-β-mediated Panc-1 epithelial-mesenchymal transition (EMT), thus decreasing cell
migration [41]. Furthermore, the activation of Kras and inactivation of p16 in immortalized
human pancreatic epithelial cells led to the upregulated expression of Nox4 and p22phox
and increased the activity of NOX [42]. In addition, the knockdown of either Nox4 or
p22phox reduced glycolysis in human PDAC cell lines and PDAC cell growth, both in vitro
and in xenograft mice.
So far, various mechanisms demonstrating how oncogenic Kras mutations regulate
PDAC cell migration and invasion have been reported. These include its regulation through
NF-κB, p53, Src, RKIP and even post-translational modifications of mutant Kras such as
sumoylation [43–47]. In this current study, our results demonstrated that a dual treatment
of NAC and recombinant CCL15 in BxPC-3 cells completely abolished the exogenously
added recombinant CCL15-induced cell migration of BxPC-3 cells (Figure 4F). This suggests
that ROS function as the downstream target of CCL15 to mediate PDAC cell migration.
Furthermore, the knockdown of Kras in Panc-1 cells diminished CCL15 protein expression
levels (Figure 5A). Both CCR1 and CCR3, receptors for CCL15, were expressed in PDAC
cells (Figures 1B,C and 2C,E). These data imply that oncogenic Kras upregulates CCL15 in
PDAC cells, allowing CCL15 to bind to its receptors on the PDAC cells, which leads to the
elevated production of ROS and subsequently increased PDAC cell migration and invasion.
This autocrine signaling mechanism is commonly utilized by PDAC cells to maximize
their own capacity for cell growth, metastasis, and drug resistance [48]. However, whether
these previously reported mechanisms involved in NF-κB, p53, Src and/or RKIP are also
associated with our newly discovered mechanism requires further investigation. Besides
CCL15 which we reported here the newly identified function of expediting PDAC cell
migration and invasion, other cytokines that have been reported to promote EMT of PDAC
through an autocrine mechanism include IL-6, IL-8, TGF-β, CCL2, and CXCL12 [49–57].
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5. Conclusions
In summary, we provided evidence that demonstrates a novel function of CCL15,
namely mediating PDAC cell migration and invasion by increasing cellular ROS levels
(Figure 6D). In addition, upregulated levels of CCL15 expression in PDAC cells were
positively associated with oncogenic Kras mutants, and the knockdown of Kras abolished
CCL15 expression, which suggests that oncogenic Kras mutations regulate CCL15 protein
expression in PDAC cells. The expression of CCL15 and its receptors CCR1 and CCR3 was
present in PDAC cells, in both cell lines and tissue samples. Altogether, our results revealed
another mechanism that PDAC cells utilize to self-promote cancer dissemination through
oncogenic KRas mutations and its downstream targets CCL15 and ROS in order to enhance
cell migration and invasion.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/cancers14092153/s1, Figure S1: CCL15 gene amplification is only
present in PDAC and may be prognostic factor for overall survival of PDAC, Figure S2: Increased
expression of CCL9 in murine metastatic PDAC, Figure S3:Quantification of CCL15 knockdown
efficiency in Panc-1 cells, Figure S4: Knockdown of CCL15 decreased Panc-1 cell migration in the
presence of bFGF, Figure S5: Inhibition of ROS by NAC treatment increased cell proliferation of
Panc-1, Figure S6: Levels of p22phox expression in Panc-1 cells that stably expressing shScramble and
shp22phox, Figure S7: Quantification of levels of Kras and CCL15 in Panc-1 cells that stably expressing
shScramble and shKras, Figure S8: Quantification of levels of N-cadherin and vimentin in Panc-1
cells, Figure S9: Knockdown of CCL9 in murine PDAC KP-2 cells reduced N-cadherin, Figure S10:
Specificity of CCR1 and CCR3 antibody used in immunohistochemistry. File S1: Original blots.
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